Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™

Core Viewpoint - Appili Therapeutics has secured new patents for its oral formulation of metronidazole, LIKMEZ, enhancing its market protection and supporting its commercialization efforts [1][2][3] Patent Protection - The newly granted patents will expire in 2039 and provide comprehensive protection for LIKMEZ, covering its unique taste-masked composition and therapeutic applications [2] - The U.S. patent has been listed in the FDA's Orange Book, which is crucial for ensuring additional protection for the formulation [2][3] Product Overview - LIKMEZ is the first FDA-approved ready-made suspension of metronidazole, specifically designed for treating antimicrobial-resistant infections, particularly beneficial for patients with dysphagia [4] - The formulation aims to improve stability and palatability, which are essential for patient adherence to medication and better treatment outcomes [3] Commercialization Efforts - Saptalis Pharmaceuticals, the partner of Appili, is planning to re-launch LIKMEZ under its own label in May 2025, leveraging the newly granted patent for commercialization activities [3][4] - The collaboration with Saptalis emphasizes the commitment to bringing innovative pharmaceutical solutions to market [5][6] Company Background - Appili Therapeutics focuses on developing therapies for infectious diseases and aims to address urgent medical needs through a diverse pipeline of anti-infectives [7][9] - The company is strategically positioned to tackle life-threatening infections, with a proven management team leading its initiatives [9]